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Frequent polymorphic changes but not
mutations of TRAIL receptors DR4 and DR5 in
mantle cell lymphoma and other B-cell lymphoid
neoplasms 
The tumor necrosis factor related apop-tosis-inducing ligand (TRAIL) is acytokine involved in the modulation of
cell survival in different cell models.1-6 Simi-
larly to other tumor necrosis factor (TNF)
family members, TRAIL mediates apoptosis
by binding to two receptors, DR4 and DR5,
with a common structural organization
characterized by an extracellular cysteine-
rich domain required for ligand binding and
an intracellular death domain essential for
the apoptotic signal transduction.7-13 Like the
homologous FAS, TRAIL receptors seem to
participate in the regulation of different
lymphoid cell populations, in particular by
preventing the expansion of autoreactive
lymphocytes and the development of auto-
immune disorders. Inactivation of the coding
for these receptors may interfere with the
normal mechanisms of cell survival facili-
tating the accumulation of abnormal lym-
phoid cell clones and eventually the devel-
opment of lymphoid neoplasms. Apoptosis-
related TNF receptors have been found to be
inactivated in several human neoplasms and
cancer cell lines. Germ-line mutations of FAS
cause an autoimmune lymphoproliferative
syndrome and an increased risk of lymphoid
malignancies.14,15 In addition, somatic muta-
tions of FAS have been detected in human
tumors, including lymphoid neoplasms.16
Similarly, mutations of the DR4 and DR5
TRAIL receptors have been found in different
types of solid tumors and occasional cases of
non-Hodgkin´s lymphoma (NHL).7,17-22 Most
of these mutations occur in the functional
death and ligand binding domains and
changes in other regions of the receptors are
extremely rare. In addition to somatic muta-
tions, several polymorphisms of regulatory
regions or functional domains of FAS and
TRAIL receptors have been frequently asso-
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Background and Objectives. Tumor necrosis factor related apoptosis-inducing ligand
(TRAIL) receptors DR4 and DR5 have been mapped to chromosome 8p21-22, a region fre-
quently deleted in different lymphoid neoplasms. 
Design and Methods. To investigate the potential alterations of these genes in lymphoid
neoplasms, we examined the presence of gene mutations in exons 3, 4, and 9 in 69 cas-
es with mantle cell lymphoma (MCL), 16 with chronic lymphocytic leukemia (CLL), 12 with
follicular lymphomas (FL) and 17 with large B-cell-lymphomas (DLBCL), as well as in 4
lymphoid cell lines carrying the t(11;14) translocation, and 91 healthy blood donors. 
Results. Three CLL and three MCL cases had 8p deletions. Two nucleotide changes in or
near the intron 3 splice consensus sequence and a silent change were found. These rare
changes were also present in the germ-line of the patients. The DR4 death domain A1322G
polymorphism was significantly more frequent in MCL [odds ratio (OR) = 5.9; 95% con-
fidence interval (CI), 1.92-18.1] and CLL (OR = 4.5; CI, 1.18-17) patients than in a sex and
age-adjusted healthy population. In contrast, the DR4 exon 4 C626G polymorphism was
associated with a significant overall decreased risk for MCL (OR = 0.3; CI, 0.12-0.8). No
mutations or cancer-associated polymorphic changes were found in DR5 domains. 
Interpretation and Conclusions. These findings indicate that mutations of DR4 and DR5
are uncommon in lymphoid neoplasms but DR4 polymorphic alleles may contribute to the
pathogenesis of these malignancies.
Key words: TRAIL receptors, mantle cell lymphoma, DR4, DR5, polymorphisms.
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ciated with different types of human tumors.6,19,24,25 Some
of these polymorphic variants seem to impair the nor-
mal functional mechanism of the receptors and may
facilitate the development or expansion of aberrant cell
clones. Thus, polymorphic changes in the FAS promoter
region have been associated with cervical squamous cell
carcinoma and acute myeloid leukemia, whereas
increased frequencies of several polymorphisms of the
TRAIL receptor DR4 death and ligand domains have been
detected in human ovarian, bladder, lung, head and neck,
and gastric carcinomas, suggesting that these polymor-
phic variants may be associated with a predisposition to
common malignancies.6,23-25
Mantle cell lymphoma (MCL) is an aggressive lymphoid
neoplasm characterized by the t(11;14) translocation
with deregulation of the cyclin D1 gene.26 The response
of this tumor to conventional chemotherapeutic treat-
ments is particularly poor with frequent relapses and
short survival. The reasons for this drug resistance are not
well known. TRAIL receptors DR4 and DR5 have been
mapped to chromosome 8p21-22,27,28 a region frequent-
ly lost in MCL (7-57%) and chronic lymphocytic leukemia
(CLL) (7%).29-31 Interestingly, 8p deletions have been asso-
ciated with clinical progression and cell transformation
in CLL, a lymphoid neoplasm in which failure of apoptotic
mechanisms seems to play a crucial pathogenic role.31 To
determine the potential role of inactivation of DR4 and
DR5 TRAIL receptors in MCL and other lymphoid neo-
plasms we examined the presence of mutations and
polymorphic variants in the ligand binding and death
domains of these genes in a large series of patients with
tumors and in the healthy population.   
Design and Methods
Case selection
Tumor specimens from 114 patients with non-
Hodgkin’s lymphoid neoplasms were obtained from the
Department of Pathology of the Hospital Clinic, Uni-
versity of Barcelona, and the Department of Pathology,
University of Würzburg, on the basis of the availability
of frozen samples for molecular studies. The patients
had given their informed consent and the study was
approved by the hospital review board. The types of
tumor were MCL (n=69), CLL (n=16), follicular lym-
phoma (FL) (n=12), and diffuse large B-cell lymphomas
(DLBCL) (n=17). Twenty-eight tumors had been ana-
lyzed by comparative genomic hybridization (CGH), and
3 cases each of CLL and MCL showed losses of chro-
mosome 8p region. We also studied REC-1, Granta-519,
JVM-2, and NCEB-1 cell lines carrying the t(11;14)
translocation and samples from 91 healthy randomly
selected blood donors. Data on age and sex were avail-
able for all included subjects.
DNA extraction and polymerase chain reaction
High molecular weight DNA was extracted from
frozen samples using the standard proteinase K/RNAse
treatment and phenol-chloroform extraction. DNA from
samples from the healthy blood donors was extracted
using the Qiagen DNA extraction kit (Qiagen, GmbH,
Germany). DNA from normal tissues or granulocytes
from a subset of patients was extracted to examine
whether the changes detected in the tumor DNA were
present in the germ-line. Polymerase chain reaction
(PCR) was performed in a total volume of 50 µL using
100 ng genomic DNA. The primers used for the ampli-
fication of the death and ligand binding domains of
DR4 and DR5 TRAIL receptors are described in Table 1.
DR4 and DR5 exon 9, coding for the death domain, was
amplified in two overlapping fragments A and B includ-
ing the intronic splicing sites and a portion of introns 8
and 9. Similarly, PCR fragments for exon 3 and 4 also
included the splicing sites and adjacent intronic regions. 
Amplifications were performed using a touchdown
PCR (step-down PCR). Conditions were: 95°C for 5 min,
three cycles with denaturation at 95°C for 30 s, anneal-
ing at 63°C for 30 s and extension at 72°C for 1 min,
three cycles with annealing at 61°C, three cycles with
annealing at 59°C, and 25 cycles with annealing at
58°C. The PCR products were electrophoresed on a 2%
agarose gel stained with ethidium bromide, and band
sizes were determined. All the amplifications were car-
ried out in a Peltier PTC-225 Thermal Cycler (MJ
Research). 
WAVE detection system for DNA sequence
changes
All amplified products were screened for the presence
of sequence changes using the WAVE system (Transge-
nomic, Omaha, NE, USA). This system consists of ion-
paired, denaturing high performance liquid chromatog-
raphy (DHPLC) that analyzes the formation of het-
eroduplexes using different melting temperatures. The
two sequences to be compared (wild type controls and
tumor samples) are denatured and reannealed prior to
DHPLC analysis to allow the formation of the original
homoduplexes and possible mismatched heteroduplex-
es due to the presence of variations in the sequence.
These heteroduplexes are thermally less stable and show
reduced retention on the chromatographic separation
matrix generating distinctly different peak profiles. In
order to identify all the potential heteroduplexes, the
chromatography was performed at three different melt-
ing temperatures. The normal and tumoral PCR products
were mixed (2:3 ratio) and denatured at 94°C for 5 min
followed by a 30-min ramp to 24°C (0.1°C/s). The dena-
tured and reannealed samples were run on the WAVE
instrument at different melting temperatures depend-
ing on the PCR products being analyzed. The gradient
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for each PCR product was calculated using WAVEMak-
er software.
Generation of mutant positive controls
In order to have a positive control of nucleotide
changes to use in the screening for gene mutations by
the WAVE system we generated mutants for exon 9 of
DR4 and DR5 by PCR technology (Figure 1). We adapt-
ed a previously described protocol for the introduction
of point mutations in the middle region of a target.32
Briefly, exon 9 of DR4 and DR5 was amplified in two
partially overlapping fragments. The longer fragment
(fragment B) covered most of the sequence except a
small 5’ region. The shorter fragment (fragment A) cov-
ered the 5’ sequence, including the sequence missing
from fragment B, and carried a single nucleotide sub-
stitution introduced by primer design. DR4 fragment A
was amplified with primers Q, carrying the mutation,
and A (Table 1). DR4 fragment B was amplified with
primers R and B. The primers used to amplify DR5 frag-
ment A were S, carrying the mutation, and I whereas the
primers for DR5 fragment B were T and J (Table 1).
Amplifications were performed using the touchdown
PCR (step-down PCR) described above. PCR products
were electrophoresed on a 2% agarose gel stained with
ethidium bromide and purified using a GenElute PCR
Clean-Up Kit (Sigma). The purified A and B fragments
were mixed 1:1 and amplified with a touchdown PCR
to generate a full exon 9 fragment that would contain
a point mutation in the middle region. First, the PCR
mix, containing fragments A and B but no primers, was
subjected to an extension step consisting of 95°C for 5
min, 94°C for 30 s, 50°C for 30 s, and 72°C for 5 min.
The primers A and B for the DR4 A mutant and I and J
for the DR5 A mutant were added afterwards and then
the PCR was performed. The mutants were elec-
trophoresed, purified, and sequenced to confirm the
nucleotide changes introduced.
DNA sequencing 
PCR products showing abnormal chromatogram pro-
files in the WAVE analysis were sequenced. The ampli-
fied products were purified using a GenElute PCR Clean-
Up Kit (Sigma) and sequenced using cycle sequencing
Table 1. Primers for PCR and sequencing.
Identification Fragment Primer Length
letter                     (Tm°C)    
TRAIL receptor DR4
A DR4-exon9-A F 5’-CCCAACTCATCTGGCTGTCT-3’ (54.3)
B DR4-exon9-A R 5-TGCATGTCTCTCTTCCATCC-3’ (52.9 273 bp
C DR4-exon 9-B F 5’-ATGAAATGGGTCAACAAAACTG-3’ (52.4)
D DR4-exon 9-B R 5’-ACACCTAAGAGGAAACCTCTGG-3’ (52.3) 206 bp
E DR4-exon 3 F 5’-TTGGCTTTTCTCTCCCTTCC-3’ (54.3)
F DR4-exon 3 R 5’-GCCCCTCACTCCACCTCT-3’ (54.4) 181 bp
G DR4-exon 4 F 5’-AGGTCAAGGGACACGTCAGG-3’(58.5)
H DR4-exon 4 R 5’-GCTTCTGTGGTTTCTTTGAGG-3’ (52.7) 219 bp
TRAIL receptor DR5
I DR5-exon 9-A F 5’-CCAACTCACCTGGCTGTCTC-3’ (54.9)
J DR5-exon 9-A R 5’-AGCGTCTCCAAGGCATCC-3’ (55.4) 263 bp
K DR5-exon 9-B F 5’-CACGATGCTGATAAAGTGGG-3’(53)
L DR5-exon 9-B R 5’-GGTCTGACTTCCTGAAGAGA-3’(58.5) 202 bp 
M DR5-exon 3 F 5’-TTCTGGGAATCCTGTGGCAT-3’ (56.6)
N DR5-exon 3 R 5’-CCCCGCATTCCACCTTTA-3’ (55.7) 208 bp
O DR5-exon 4 F 5’-TTCCCAAAACCTTATGCTCTG-3’ (52.8)
P DR5-exon 4 R 5’-GGGGTTCCATGGAGCTACTG-3’ (55.6) 183 bp
Generation of positive controls
Q DR4-exon 9-mut-F 5’-CAGCATTGCTTACAAGGCAT-3’(52.7)
R DR4-exon 9-cut-R 5’-ACCCAGCTCTGATGCTGTTC-3’(54.4)
S DR5-exon 9-mut-F 5’-CCTCAGCATTAGCCACCTTT-3’(53)
T DR5-exon 9-cut-R 5’-CAGTGCTTCGATGACTTTGC-3’ (53.6) 
Effect at expression level of mutants of TRAIL receptor DR4 
U DR4-exon3+4 F 5’-GGAGCCTGTAACCGGTGCAC-3’ (58.9)
V DR4-exon3+4 R 5’-CTTCCGGCACATCTCAGCAG-3’ (58.2)
W DR4-exon3+intron3 F 5’-CAGCTTGTAAATCAGCCTGGAGT-3’ (52.9) 
X DR4-exon3+intron3 R 5’-CCCTCTTGGAGCTGATAGTTTG-3’ (53.8)
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with BigDye Terminator chemistry (Applied Biosystems,
Foster City, CA, USA). Sequencing reactions were run on
an Abi Prism ABI-3100 automated sequencer. All
nucleotide changes were confirmed by sequencing both
strands.
RNA extraction and reverse transcription PCR
Total RNA was obtained from frozen tissues using
guanidine isothiocyanate extraction and cesium chloride
gradient centrifugation. For cDNA synthesis, 1 µg of
RNA and Taqman Reverse Transcriptions reagents
(including Multiscribe™ reverse transcriptase and ran-
dom hexamers) were used, as described by the manu-
facturer (Applied Biosystems). To examine the presence
of the nucleotide change G1405T (Stop469Leu) of DR4
exon 9 in a sample for which only RNA was available,
the coding region was amplified using primers C and D
as described above. The potential effect at the RNA lev-
el of the two nucleotide changes detected in the TRAIL-
R1/DR4 exon 3-intron 3 splicing region was studied by
amplifying exon 3 and exon 4 coding regions near the
exon-intron boundaries with primers U (exon 3) and V
(exon 4); and exon 3-intron 3 with the primers W
(including the splicing site nucleotide change) and X
(intron 3).
Immunohistochemistry
DR4 protein expression was examined immunohisto-
chemically on formalin-fixed, paraffin-embedded tis-
sues using a murine monoclonal antibody (HS101)
(Alexis Biochemicals, UK), standard antigen retrieval
protocols, the Envision detection system (Dakocytoma-
tion, Carpinteria, CA, USA) and the automated immu-
nostainer TechMate 500 Plus (Dako). 
Statistical analyses
Differences in allele and genotype frequencies were
determined among controls using the χ2 test. Allele fre-
quencies in the control group were evaluated for the
Hardy-Weinberg equilibrium. The p value among con-
trols for the A1322G polymorphism was 0.6, for the
C626G it was 0.5 and for the G422A was 0.6. To test the
hypothesis of an association between the different
polymorphisms and lymphoid malignancies, multivari-
ate methods were used based on logistic regression
analysis. Cases were divided into groups and polyto-
mous logistic regression was used comparing each
group of cases with the whole set of controls. Odds
ratios (OR) and 95% confidence intervals were calcu-
lated for each age (in tertiles) and sex adjusted group.
Homozygosity for the more frequent allele among con-
trols was set as the reference class for polymorphisms.
The linear trend of the OR was tested using the cate-
gorized variable as quantitative after assigning a linear
score to each ordered category.
Results
DR4 death domain 
TRAIL receptor DR4 death domain is necessary for the
transduction of the apoptotic signal and is encoded by
exon 9. The majority of the DR4 mutations described in
human tumors, including several types of lymphomas,
have been detected in this region.7;17-22 The analysis of
the 69 cases of MCL showed an anomalous pattern of
DNA mobility in 24 (34.8%) of them (Figure 2). All ca-
ses showed an identical mobility profile, suggesting that
it could correspond to a polymorphic variant. Sequenc-
ing analysis revealed that this anomalous pattern was
due to the known polymorphism, A1322G, resulting in
the conversion of the lysine at codon 441 to arginine.
Only one of these 24 cases was homozygous for this
variant. This polymorphism has been previously
described in several cancer cell lines, human tumors,
and in 2 of 10 (20%) healthy volunteers. This change
seems to make the DR4 receptor less sensitive to the
TRAIL signal.6 To examine whether this polymorphism
was more frequent in patients with MCL than in the
healthy population we examined 91 DNA samples from
normal controls. The A1322G polymorphism was signif-
Figure 1. Generation of WAVE mutant positive controls.
DR4 and DR5 exon 9 were amplified in two partially over-
lapping fragments: fragment A, which was the shorter of
the two and carried the mutation (by amplification with
mutated primer Q in DR4 or S in DR5, Table 1), and frag-
ment B. Purified A and B PCR products were mixed 1:1
and subjected to a reannealing and extension step prior
to amplification. The PCR products generated contained
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icantly more common among patients with MCL, being
present in 24 of 69 tumor samples (34.8%), as com-
pared to in 16 of the 91 (17.6%) control samples. In
MCL, the age- and sex-adjusted odds ratio (OR) for the
presence of the G allele was 5.9 (95%CI=1.92-18.1); 5.2
(95% CI=1.64-16.1) in heterozygosis and 24.7 (95%
CI=1.04-587.6) for the homozygous variant of the
altered allele (Table 2). 
To determine the possible presence of DR4 death
domain mutations and the incidence of the A1322G
polymorphism in other lymphoid neoplasms, the whole
DR4 exon 9 was screened in 16 CLL, three of them with
8p deletions, 12 FL, 17 DLBCL and the four human lym-
phoid cell lines carrying the t(11;14) translocation. No
mutations were detected in any of these cases. How-
ever, the A1322G polymorphism was observed in 6
(37.5%) CLL cases, which was a significantly higher
incidence than that in the controls (OR=4.5, 95% CI =
1.18-17). The polymorphism was identified in only in 1
(8.3%) FL and 3 (17.6%) DLBCL with an incidence sim-
ilar to that in the normal population (Table 2). None of
the cell lines analyzed had the polymorphic variant. Two
samples from normal controls showed an abnormal pat-
tern in their WAVE chromatograms, different from the
characteristic A1322G profile (Figure 3). Cycle sequenc-
ing revealed a heterozygous alteration at nucleotide
1405 changing a guanine to thymine (G1405T) which
leads to a substitution of the normal 469 stop codon for
a leucine. This modification would encode for a puta-
tive DR4 protein variant with 14 additional amino acids.
Intriguingly, one of these two normal individuals had a
sister with acute myeloid leukemia who also shared this
alteration in heterozygosity. This change was not
detected in any of the 114 lymphoid tumors.
Figure 2. Polymorphisms in TRAIL receptors DR4 and DR5. Panels A, B, C and D represent the chromatogram (upper
panel) and sequence (lower panel) of different DR4 and DR5 polymorphisms: (A) A1322G in the death domain of DR4;
(B) G422A in the extracellular domain of DR4; (C) C626G in the extracellular domain of DR4; (D) intronic polymor-
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DR4 ligand-binding domain
A mutational analysis of exons 3 and 4 of TRAIL
receptor DR4 was performed in the same series of MCL
and other lymphoid neoplasms described above. These
exons codify for the principal elements of the extracel-
lular cysteine-rich domain of the receptor required for
TRAIL binding. Sequence alterations in this region may
lead to deficient ligand binding and affect the down-
stream apoptotic signaling.23
Screening the genomic DNA revealed an abnormal
chromatogram of the exon 3 fragment in two cases of
typical MCL and one case of CLL. Sequencing analysis
of these cases demonstrated three different nucleotide
changes in the tumors (Figure 3). One MCL had a change
in the splice site conserved sequence AGGT at the exon
3-intron 3 boundary, changing a guanine to cytosine at
position +1 of intron 3. The second MCL had a change
near the splicing site at position +6 of intron 3, also
changing a guanine to cytosine. The CLL showed a silent
change at nucleotide 465 changing an adenine for a
cytosine (Thr155Thr). All three cases were heterozygous
for the altered allele. These changes were also detect-
ed in the germ-line of the patients but in none of the
91 healthy controls. To analyze the potential effect of
these changes at the RNA level, cDNA from the two
cases of MCL was generated and amplified with two
different sets of primers. The first set consisted in
primers which amplified exon 3 and exon 4 coding
regions near the exon-intron boundaries and the sec-
ond set consisted in a forward primer that carried the
mutation corresponding to each case, and a reverse
primer which annealed to a near region in intron 3
(Table 1). Genomic DNA from the cases was used as the
positive control. No anomalous transcripts were detect-
ed in these lymphomas suggesting that these changes
may not be functionally relevant.
In addition to these distinct chromatograms, two
anomalous profiles were detected in more than one case
suggesting that they could correspond to polymorphic
variants (Figure 2). Sequencing analysis revealed two
previously described polymorphisms: G422A and C626G
at exon 3 and 4, respectively.23 These changes result in
a substitution of a histidine for arginine and an arginine
for threonine, respectively. These two polymorphic vari-
ants seem to co-segregate homozygously in patients
with lung, head and neck, and gastric cancer, in whom
their incidence is significantly higher than in healthy
controls.23 To determine whether these polymorphisms
were differentially represented in patients with lym-
phoid neoplasms we also screened a series of 91 healthy
Table 2. Allele frequency of A1322G in non-Hodgkin´s lymphomas and odds ratio in relation to frequencies in controls.






A/G + G/G 16 17.6
MCL 69 10.6 0.0011
A/A 45 65.2 1 -
A/G 23 33.3 5.2 (1.64-16.1)     
G/G 1 1.5 24.7 (1.04-587.6)
A/G + G/G 24 34.8 5.9 (1.92-18.1)
CLL 16 5.9 0.0148
A/A 10 62.5 1
A/G 5 31. 3.7 (0.92-14.9)
G/G 1 6.3 22.6 (1.03-495.9) 
A/G + G/G 6 37.5 4.5 (1.18- 17) 
FL 12 0.2 0.6985
A/A 11 91.7 1
A/G 1 8.3 0.7 (0.07-6.2)     
G/G 0 0 0
A/G + G/G 1 8.3 0.7 (0.07-6.7)
DLBCL 17 0.03 0.8625
A/A 14 82.3 1
A/G 3 17.6 1.3 (0.29-5.6)    
G/G 0 0 0
A/G + G/G 3 17.6 1.3 (0.29-5.5) 
1OR: odds ratio; OR are adjusted for sex and age in tertiles; 2p-value for test of linear trend.
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controls. The distribution of the CC, CG, and GG alleles
of exon 4 C626G polymorphism in the different lym-
phoma types is shown in Table 3. The frequency of the
alleles was similar in CLL, FL, DLBCL and the control
population after adjustment for age and sex. However,
the presence of the G allele was associated with an
overall significant protective effect in MCL compared to
in the controls (OR=0.3, 95%CI=0.12-0.8). The G422A
variant was also observed at the same allelic frequen-
cy in all types of lymphoid tumors and controls (data not
shown). Interestingly, a significant association between
the homozygous A allele of this polymorphism and the
homozygous G allele of codon 626 was observed in MCL
since 7 of the 14 MCL patients (50%) homozygous for
the 422 AA allele were also homozygous for the 626 GG
allele whereas this association was only detected in 3
of the 27 (11%) controls homozygous for the G422A
polymorphism (p=0.04). 
To determine whether these polymorphic variants
were associated with different DR4 protein expression
we examined 12 cases of MCL by immunohistochem-
istry: 6 had the A1322G variant, 8 the C626G variant
and 9 the G422A variant. The intensity of DR4 expres-
sion was similar in all cases, indicating that DR4 is
expressed in all MCL independently of the polymorphic
variant. 
DR5 death and ligand-binding domains 
The TRAIL receptor DR5 death and ligand-binding
domains were similarly examined in the 114 lymphoid
neoplasms and 91 healthy controls. No mutations or
polymorphic variants were detected in the coding regions
or splicing sites of exons 3, 4 or 9, of any of the tumors
or controls analyzed. Only a common nucleotide change
(T for a C) in intron 2, at position -21 from the start of
exon 3, was observed in most of the cases studied. The
Figure 3. Nucleotide changes in TRAIL receptor DR4. Panels A, B, C and D represent the chromatograms (upper pan-
els) and sequences (lower panels) of different nucleotide changes: (A) G1405T in the death domain; (B) silent muta-
tion A465C at exon 3, in the extracellular domain; (C) G→C at position +1 of the splicing donor site of intron 3; (D)
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frequencies ranged from 77% to 100% in different lym-
phoma groups, and 86% in normal controls indicating
that this must be the most common DR5 sequence in the
control population (Figure 2). No significant differences
were observed between the different lymphoid tumors
and the healthy population. 
Discussion
DR4 and DR5 TRAIL receptors have been mapped to
chromosome 8p21-22 bands.10,33 This genetic region is
frequently deleted in different human tumors suggest-
ing that it may harbor a potential tumor suppressor gene.
Inactivating mutations of DR4 and DR5 receptors have
been associated with loss of heterozygosity in some
tumors, indicating that these genes may be potential tar-
gets of 8p deletions.18,20 DR4 and DR5 mutations have
been observed in head and neck squamous cell carcino-
mas, non-small cell lung carcinomas, breast and gastric
cancers, and non-Hodgkin´s lymphomas. Most of these
mutations were detected in the death domain and
intronic sequences of the genes and consisted of mis-
sense alterations and less frequently non-sense, micro-
deletions, splice-site, and silent mutations.7,17-22,34,35
In our study, we detected three nucleotide changes in
the DR4 extracellular domain of two patients with MCL
and one with CLL. These changes involved position +1 of
the intron 3 splice-site donor consensus sequence and
position +6 of the same intron in the two cases of MCL
respectively, and a silent mutation in codon 155 in the
CLL. These three changes were in heterozygosis and were
not detected in any of the control samples examined.
However, they were also present in the germ-line of the
patients and the changes in the splicing sites were not
associated with anomalous transcripts, suggesting that
they may be rare polymorphisms with no apparent func-
tional significance. Deletions of chromosome 8p were
found in 6 tumors (3 CLL and 3 MCL) but none of these
cases had mutations in the DR4 extracellular domain.
This lack of inactivating mutations in our study is in con-
trast with the only previous report on non-Hodgkin’s
lymphomas in a  Korean population in which 7% of the
tumors showed potential inactivating mutations in the
death domain of DR4 or DR5 genes.17 This difference may
be due in part to the spectrum of tumors examined since
the previous study included only 3 MCL, 7 CLL, and 4 FL
whereas mutations were detected in 5 of 46 (11%) DLB-
CL, 2 of 23 (9%) MALT lymphomas and 1 of 14 (7%)
peripheral T-cell lymphomas. However, a similar differ-
Table 3. Allele frequency of C626G in non-Hodgkin´s lymphomas and odds ratio in relation to frequencies in controls.






C/G + G/G 65 71.4
MCL 69 3.5 0.0633   
C/C 34 49.3 1 −
C/G 17 24.6 0.4 (0.12-1.1)
G/G 18 26.1 0.4 (0.12-1.1)
C/G + G/G 35 50.7 0.3 (0.12-0.8)
CLL 12 2.4 0.1198
C/C 2 16.7 1 −
C/G 2 16.7 0.6 (0.08-4.9)
G/G 8 66.7 3.6 (0.62-20.8) 
C/G + G/G 10 83.3 1.6 (0.31-8.6)
FL 12 0.5 0.4884
C/C 5 41.7 1 −
C/G 3 25.0 0.5 (0.09-2.5)
G/G 4 33.3 0.6 (0.12-2.8)
C/G + G/G 7 58.3 0.5 (0.12-1.8)
DLBCL 17 2.1 0.1454
C/C 5 29.4 1 −
C/G 1 5.9 0 −
G/G 11 64.7 2.4 (0.66-9.0) 
C/G + G/G 12 70.6 0.8 (0.24-2.7) 
1OR: odds ratio; OR are adjusted for sex and age in tertiles; 2p-value for test of linear trend.
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ence in the incidence of TRAIL receptor mutations in
Korean and Western populations has been observed in
solid tumors. Thus, DR4 or DR5 mutations were noted in
11% of non-small cell lung cancers (NSCLC) and 30% of
metastasic breast carcinomas in the Korean population,
but in only 3% of head and neck carcinomas, and in none
of a large series of NSCLC and breast tumors in Western
patients, suggesting a possible population-based differ-
ence in the mutation pattern of these genes.18-21,36 
Although DR4 and DR5 inactivating mutations were
not detected in our series, two polymorphic changes in
the DR4 death and ligand binding domains were more
frequently detected in different types of lymphoid neo-
plasms than in the normal control population. The DR4
death domain A1322G polymorphism was present in
37.5% and 34.8% of CLL and MCL patients, respective-
ly, but in only 17.6% of the control population. These
differences were statistically significant when compared
to a sex- and age-adjusted healthy population, suggest-
ing that this polymorphism may be associated with an
increased risk of developing these tumors. The allelic fre-
quencies in FL and DLBCL were similar to those in the
normal controls. Transfection experiments in ovarian and
bladder cancer cell lines have shown that this polymor-
phism has a dominant negative effect in DR4-mediated
killing, rendering cells more resistant to TRAIL.6 Although
this polymorphism may not alone justify complete resist-
ance to TRAIL, its dominant negative effect in vitro may
explain its heterozygous predominance and suggest a
certain contribution to apoptotic resistance facilitating
the development of CLL and MCL neoplastic clones.6,19
Two additional polymorphisms in the DR4 ligand-bind-
ing domain, G422A and C626G, have been associated in
homozygosis with an increased risk of different solid
tumors. Thus, G422A was found to be associated with
gastric, lung, and head and neck cancers whereas C626G
was found to be overrepresented in lung, and head and
neck tumors.23 In contrast, the C626G polymorphism had
a protective effect in patients with bladder cancer. The
DR4 extracellular domain was not examined in the pre-
vious study of NHL and, therefore, no information on the
distribution of these polymorphisms in lymphoid neo-
plasms is available.17 In our study, the frequency of the
G422A allele was similar in all types of lymphomas and
healthy controls. However, the C626G variant was asso-
ciated with a significant protective effect for MCL. In
urinary bladder carcinomas, the protective effect of this
polymorphism was mainly associated with young, light
smokers suggesting an association between the devel-
opment of the tumor, the DR4 polymorphism, and envi-
ronmental exposure.37 Epidemiological risk factors in MCL
have not been studied and, therefore, the possible rela-
tionship of this association and an environmental expo-
sure in such patients is not known. The GG and AA
homozygous variants of the 626 and 422 polymorphisms
co-segregated in 44-48% of patients with head and
neck, lung and gastric carcinomas.23 Interestingly, the fre-
quency of being homozygous for both alleles was also
significantly higher in MCL patients than in controls,
suggesting that this association may be common in dif-
ferent types of tumors. The functional effect of these
polymorphisms is currently unknown. However, their
location flanking the receptor ligand interface regions
suggest that sequence changes  may alter binding of the
ligand to the receptor and apoptotic signaling. 
Since TRAIL has a selective action, being more apop-
totic to tumor cells than to normal cells, it has been sug-
gested that it could be used as a new therapeutic strat-
egy.38,39 However, the sensitivity of different tumors to
TRAIL-induced apoptosis is variable and the determi-
nants of the different responses are not well known. Pri-
mary CLL cells and other hematologic malignancies may
be resistant to the TRAIL effect.13,40 The causes of this
resistance appear to be complex, involving different fac-
tors such as variable levels of expression of the receptor
and other elements of the downstream pathway.13 The
rare presence of inactivating mutations in DR4 and DR5
genes in our series of lymphoid neoplasms, including 6
cases with 8p deletions, indicate that these alterations
are not relevant cause of TRAIL resistance. However, the
relatively high frequency of several DR4 polymorphisms
with a potential functional effect in MCL and CLL sug-
gests that polymorphic variants may play a role in TRAIL
resistance in such neoplasms. In addition, the signifi-
cantly different frequencies of these polymorphic vari-
ants in tumors compared with in the normal population
suggests that they may also act as genetic modulators in
the development of certain malignancies.
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